SNDX Syndax Pharmaceuticals Inc

USD 23.80 0.73 3.164283
Icon

Syndax Pharmaceuticals Inc (SNDX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 23.80

+0.73 (+3.16)%

USD 1.92B

1.06M

USD 35.33(+48.46%)

USD 0.00 (-100.00%)

Icon

SNDX

Syndax Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 23.80
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.92B

USD 0.00 (-100.00%)

USD 23.80

Syndax Pharmaceuticals Inc (SNDX) Stock Forecast

Show ratings and price targets of :
USD 35.33
(+48.46%)

Based on the Syndax Pharmaceuticals Inc stock forecast from 9 analysts, the average analyst target price for Syndax Pharmaceuticals Inc is USD 35.33 over the next 12 months. Syndax Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Syndax Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Syndax Pharmaceuticals Inc’s stock price was USD 23.80. Syndax Pharmaceuticals Inc’s stock price has changed by +4.02% over the past week, -0.34% over the past month and +11.63% over the last year.

No recent analyst target price found for Syndax Pharmaceuticals Inc
No recent average analyst rating found for Syndax Pharmaceuticals Inc

Company Overview Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearr...Read More

https://www.syndax.com

35 Gatehouse Drive, Waltham, MA, United States, 02451

184

December

USD

USA

Adjusted Closing Price for Syndax Pharmaceuticals Inc (SNDX)

Loading...

Unadjusted Closing Price for Syndax Pharmaceuticals Inc (SNDX)

Loading...

Share Trading Volume for Syndax Pharmaceuticals Inc Shares

Loading...

Compare Performance of Syndax Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for SNDX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Syndax Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S +0.35 (+0.27%) USD554.45B 46.01 4.80

ETFs Containing SNDX

Symbol Name SNDX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Syndax Pharmaceuticals Inc (SNDX) Stock

Based on ratings from 9 analysts Syndax Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and 2 hold ratings.

Unfortunately we do not have enough data on SNDX's stock to indicate if its a good dividend stock.

Based on targets from 9 analysts, the average taret price for SNDX is USD 35.33 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 23.

Unfortunately we do not have enough data on SNDX's stock to indicate if its overvalued.

The last closing price of SNDX's stock was USD 23.80.

The most recent market capitalization for SNDX is USD 1.92B.

Based on targets from 9 analysts, the average taret price for SNDX is projected at USD 35.33 over the next 12 months. This means that SNDX's stock price may go up by +48.46% over the next 12 months.

We can't find any ETFs which contains Syndax Pharmaceuticals Inc's stock.

As per our most recent records Syndax Pharmaceuticals Inc has 184 Employees.

Syndax Pharmaceuticals Inc's registered address is 35 Gatehouse Drive, Waltham, MA, United States, 02451. You can get more information about it from Syndax Pharmaceuticals Inc's website at https://www.syndax.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...